In a keenly-awaited decision (T 0056/21) issued today, Technical Board of Appeal 3.3.04 (Pregetter, Bühler, Luis Alves) has unexpectedly decided not to refer to the Enlarged Board of Appeal questions about the legitimacy of the European Patent Office’s long-standing practice of requiring that the description of European patent applications be amended before grant for consistency with the allowable claims.
This is a controversial area of EPO practice, and a referral to the Enlarged Board of Appeal was widely expected after a preliminary opinion from the Board indicated that it intended to make such a referral.
The Board has, however, held that there is no basis for this requirement in Art 84 EPC, nor in Rules 42, 43 and 48, which have often been cited in support of this practice.
Chris is a Partner and Patent Attorney at Mewburn Ellis. He is proficient in prosecution, opposition and appeal work at the European Patent Office. Chris also provides associated litigation support in the biotech field, especially biopharmaceuticals, from early stage research through to lifecycle management of approved blockbuster products. He has particular experience of large portfolio management, including diverse portfolios arising from large research programmes and those centred about particular products.
Email: chris.denison@mewburn.com
Our IP specialists work at all stage of the IP life cycle and provide strategic advice about patent, trade mark and registered designs, as well as any IP-related disputes and legal and commercial requirements.
Our peopleWe have an easily-accessible office in central London, as well as a number of regional offices throughout the UK and an office in Munich, Germany. We’d love to hear from you, so please get in touch.
Get in touch